UK rejects Gilead’s CAR-T cancer cell therapy as too expensive
LONDON (Reuters) – A cutting-edge CAR-T cell therapy for otherwise untreatable forms of blood cancer is too expensive to justify…
Doctor in eastern Congo contracts Ebola in ‘dreaded’ scenario: WHO
GENEVA (Reuters) – A doctor has become the first probable Ebola case in one of the eastern Democratic Republic of…
China sacks six senior officials at food and drug regulator over vaccine scandal
SHANGHAI (Reuters) – China said on Saturday it has sacked six senior officials at its food and drug regulator after…
Long-acting injection a shot in the arm for GSK’s HIV business
LONDON (Reuters) – A long-acting injection developed by GlaxoSmithKline (GSK.L) and given once a month has proved as effective as…
Biogen’s pricey muscle drug Spinraza too costly for Britain
LONDON (Reuters) – Biogen’s muscle disease treatment Spinraza has been deemed too expensive for use on Britain’s state-run health service,…
FDA declines to approve Insys Therapeutic’s opioid painkiller
(Reuters) – Insys Therapeutics Inc said on Friday the U.S. Food and Drug Administration declined to approve its opioid painkiller,…
GSK’s new R&D head bets on genetics with $300 million 23andMe deal
LONDON (Reuters) – GlaxoSmithKline’s new research boss aims to turbo-charge the British group’s drug discovery engine with a $300 million…
Bitter pill: China vaccine scandal sparks online fury, roils markets
SHANGHAI (Reuters) – A vaccine scandal in China, which has prompted angry reactions from leaders and citizens fed up with…
Mersana’s cancer drug trial put on hold by FDA; shares halted
(Reuters) – Mersana Therapeutics said on Thursday an early stage trial testing its lead cancer drug has been put on…
Allergan, Molecular Partners eye drug meets main goal in two studies
(Reuters) – Allergan Plc and Molecular Partners AG said on Thursday their treatment for neovascular age-related macular degeneration, a leading…
CRISPR gene editing can cause risky collateral DNA damage: study
LONDON (Reuters) – Scientists studying the effects of the potentially game-changing gene editing tool CRISPR/Cas9 have found it can cause…
CTI Biopharma’s cancer drug fails late-stage trial, shares tumble
(Reuters) – CTI Biopharma Corp said on Monday its treatment for a type of blood cancer did not meet the…
Amazon to buy PillPack in potentially disruptive drug retail push
(Reuters) – Amazon.com Inc said on Thursday it would buy small online pharmacy PillPack, a move that will put the…
Ex-Akebia employee jailed for night as insider trading trial starts
BOSTON (Reuters) – A former Akebia Therapeutics Inc (AKBA.O) employee accused of engaging in an insider trading scheme must spend…
GSK’s two-drug HIV treatment meets main goal in late stage studies
(Reuters) – GlaxoSmithKline’s two-drug treatment for HIV, the virus that causes AIDS, met its main goal in late stage studies,…
Many women with early-stage breast cancer can skip chemotherapy: study
CHICAGO (Reuters) – Some 70 percent of women with early-stage breast cancer and an intermediate risk of cancer recurrence can…
Experts outline ethics issues with use of genealogy DNA to solve crimes
(Reuters Health) – With recent revelations that U.S. law enforcement can – and already has – dipped into consumer genealogy…
Novartis readies anti-sexism message for migraine drug
ZURICH (Reuters) – With women hardest hit by migraine headaches, Swiss drugmaker Novartis is gearing up its marketing message to…
Leading oncology group wary of Trump drug price proposals
CHICAGO (Reuters) – America’s leading group of cancer doctors is wary of new Trump administration proposals for lowering drug costs,…
FDA approves BioMarin rare metabolic disorder drug, shares rise
(Reuters) – U.S. regulators on Thursday approved BioMarin Pharmaceutical Inc’s Palynziq for adults with phenylketonuria, a rare metabolic disorder, sending…
Evolus investors frown as FDA declines to approve Botox rival
(Reuters) – U.S. health regulators on Wednesday declined to approve Evolus Inc’s (EOLS.O) rival product to Allergan Plc’s (AGN.N) Botox,…
Evolus investors frown as FDA declines to approve Botox rival
(Reuters) – U.S. health regulators on Wednesday declined to approve Evolus Inc’s (EOLS.O) rival product to Allergan Plc’s (AGN.N) Botox,…
Jazz Pharmaceuticals to settle U.S. probe for $57 million
BOSTON (Reuters) – Jazz Pharmaceuticals Plc said on Tuesday it had agreed to pay $57 million to resolve a U.S.…
FDA chief questions protections on drug rebates, stocks fall
(Reuters) – U.S. Food and Drug Administration chief Scott Gottlieb on Thursday questioned whether rebates that drugmakers provide to health…
Scientists devise new, more accurate peanut allergy test
LONDON (Reuters) – British scientists have developed a far more accurate blood test to diagnose peanut allergy, offering a better…
Regeneron/Sanofi cut heart drug price to $4,500-$6,600 for Express Scripts
(Reuters) – Regeneron Pharmaceuticals Inc and Sanofi SA will slash the price of their expensive cholesterol drug for Express Scripts…
FDA clears Pluristem radiation treatment for emergency use
HAIFA, Israel (Reuters) – Pluristem Therapeutics Inc, a developer of placenta-based stem cell products, said the U.S. Food and Drug…
High-profile investors bet on stocks tied to millennials: Sohn Conference
NEW YORK (Reuters) – Hedge fund managers at the high-profile 2018 Sohn Investment Conference in New York pitched stock ideas…
FDA approves Ultragenyx’s drug for rare form of rickets
(Reuters) – The U.S. Food and Drug Administration has approved Ultragenyx Pharmaceutical Inc’s treatment for a rare and inherited form…
Biotech M&A rolls on as Alex ion snaps up Wilson for $855 mln
(Reuters) – Alex ion Pharmaceuticals has agreed to buy Sweden’s Wilson Therapeutics for 7.1 billion Swedish crowns ($855 million), boosting…
Medical studies in humans often launched on faulty evidence base
(Reuters Health) – New research reveals serious flaws in the animal studies that regulators and ethicists use to decide if…
Pfizer signs deal with Allogene to develop cancer cell therapy
(Reuters) – Pfizer Inc said on Tuesday it signed an agreement with Allogene Therapeutics, a company formed by a consortium…
FDA refuses to review Alkermes’ depression treatment, seeks more trials
(Reuters) – Alkermes Plc has been told to conduct more clinical trials of its experimental depression treatment after the U.S.…
Esperion’s drug clears study as add-on cholesterol treatment
(Reuters) – Esperion Therapeutics Inc said on Tuesday its experimental oral drug met the main goal of reducing cholesterol by…
Biohaven plunges as investors pit migraine data against Allergan’s drug
(Reuters) – Biohaven Pharmaceutical Holding said its treatment for acute migraine cleared two late-stage studies, but investors worried about its…
Bolivian women weave devices to patch holes in hearts
(Reuters Health) – A team of Bolivian women are using indigenous Aymara weaving patterns to craft devices that can help…